Key Highlights
- Cardinal Health elevated its fiscal-year adjusted EPS outlook to $10.70–$10.80 from the prior range of $10.15–$10.35.
- Third-quarter adjusted EPS reached $3.17, surpassing the Street’s $2.79 projection.
- Total revenue climbed 11% to $60.9 billion, falling short of the $62.1 billion analyst forecast.
- Net earnings declined to $399 million from $506 million, impacted by a $184 million goodwill impairment.
- Shares of CAH advanced 1.6% during premarket hours on Thursday.
Cardinal Health delivered an upward revision to its annual profit projection for the second consecutive time this fiscal year, capturing investor attention. Shares climbed 1.6% in premarket action Thursday, reaching $205.99.
Management elevated its adjusted earnings forecast to a range of $10.70 to $10.80 per share for fiscal 2026. This represents a meaningful upgrade from the February projection of $10.15 to $10.35. The consensus among analysts stood at approximately $10.31 per share.
The improved outlook provided significant support for the stock. Meanwhile, the quarterly results presented contrasting signals.
Adjusted earnings per share hit $3.17, comfortably outpacing the $2.79 consensus figure. This type of earnings surprise typically generates positive market response.
Revenue results painted a more complicated picture. Overall sales increased 11% from the prior-year period to $60.9 billion, yet missed the $62.1 billion target analysts had forecast.
The pharmaceutical and specialty solutions division accounted for the bulk of top-line expansion, generating $56.1 billion in revenue, representing an 11% gain compared to last year’s corresponding quarter.
The global medical products and distribution division struggled to contribute. Sales in this segment remained essentially unchanged year-over-year, weighed down by reduced distribution activity.
Earnings Decline Despite Revenue Growth
Net income fell to $399 million from $506 million recorded in the same quarter last year. The primary factor behind this decline was a $184 million pretax goodwill impairment charge.
This charge stemmed from Cardinal’s oncology practice alliance and its Integrated Oncology Network, an asset the company brought into its portfolio in late 2024.
While goodwill impairments don’t represent actual cash outflows, they indicate that an acquired business is underperforming relative to initial purchase expectations. Such charges warrant careful consideration.
Evercore ISI analyst Elizabeth Anderson characterized the performance as “solid,” pointing out that the pharmaceutical revenue shortfall primarily resulted from wholesale acquisition costs — essentially a passthrough matter rather than a core business weakness.
Specialty Pharmaceutical Momentum Supports Projections
Cardinal, alongside industry peers Cencora and McKesson, continues benefiting from robust demand for high-margin specialty pharmaceutical products. Medications addressing cancer and autoimmune conditions represent an expanding portion of the distribution portfolio.
Biosimilar launches for formerly patent-protected blockbuster medications are contributing additional volume. These product categories enable distributors to extract greater value compared to conventional generic drugs.
Cardinal has systematically broadened its specialty care presence through strategic acquisitions of physician practices and specialty distribution networks. The Integrated Oncology Network transaction formed part of this broader initiative.
This strategic direction has encountered some challenges — the current quarter’s impairment charge demonstrates this reality. Nevertheless, leadership remains committed to this pathway.
The upgraded full-year projection, marking the second such increase in consecutive quarters, signals management’s optimism regarding performance in the remaining fiscal period.
Cardinal Health’s fiscal third quarter concluded on March 31. Shares traded up 1.6% in premarket activity at $205.99 at the time of this report.
